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ABSTRACT 
 
Influence of Fibroblasts on Functional Arteriogenesis in a Murine Chronic Hindlimb 
Ischemia Model 
 
Ashli Agamata Santos 
 
Peripheral arterial occlusive disease (PAOD) occurs when there is a narrowing or 
blockage – usually a buildup of plaque - within the arteries that reduces blood flow to 
tissues which can chronic ischemia. As with most diseases, early detection and proactive 
treatment are important to maximize prognosis. Exercise effectively treats PAOD, but 
due to ischemic pain in the limbs, or intermittent claudication (IC), exercise can become 
painful and difficult. Due to the buildup of plaque, occlusions create an ischemic 
environment that changes the pressure distribution in collateral networks and increases 
the shear stress in transverse collaterals. Those two responses signal the beginning of 
arteriogenesis- the enlargement of natural bypass collaterals, which can alleviate IC and 
allow patients to exercise more comfortably. Arteriogenesis is controlled by macrophages 
and growth factors to induce proliferation in endothelium and smooth muscles cells 
(SMCs); enlarging arteries allow more blood to flow and oxygen to be transported. In this 
study, fibroblast-containing collagen constructs were transplanted under the gracilis 
muscle of mice with a ligated femoral artery to confirm their beneficial contribution to 
arteriogenesis. Collagen constructs were also found to improve functionality of muscle 
force production 7-days post femoral artery ligation. Though force-intensity found no 
statistical significant between collagen constructs and fibroblast-containing collagen 
constructs, they were both found to be an improvement from the baseline disease state. 
Force-frequency data found fibroblast-containing collagen constructs to be an 
improvement from the baseline disease state while being similar to the control, non-
disease state. The PowerLab data acquisition unit (DAQ) and force transducer set-up is a 
novel method to quantify the efficacy of myogenic cells to functionally treat ischemic 
diseases and optimistic results of this study along with research based data acquisition 
improvements suggest more robust and meaningful results in a multi-operator class 
setting. 
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Chapter 1: INTRODUCTION 
Clinical Relevance 
Cardiovascular (CV) disease in the leading cause of death globally and accounts 
for 17.3 million deaths per year, and is expected to grow to 23 million by 2030 [24]. 
According to the American Heart Association, CV diseases “kill more people than all 
forms of cancer combined” with costs totaling to be more than $320.1 billion [24]. 
Coronary Heart Disease (CHD) is the most common type of CV disease that kills 
370,000 people and affects 735,000 in America alone [4]. Another CV disease, peripheral 
arterial occlusive disease (PAOD), affects 8-12 million Americans each year and evenly 
affects men and women [12]. The sheer number of people affected by ischemic disease 
and the fact that current treatments for ischemic diseases are inadequate and not 
applicable to the entire patient population warrant further research of therapies that mimic 
or promote the body’s innate response to ischemia. 
 
Peripheral Arterial Occlusive Disease and Atherogenesis  
PAOD occurs when there is a narrowing or blockage within the arteries that carry 
blood from the heart to extremities and is usually due to the buildup of plaque along 
artery walls (Figure 1). Although PAOD equally affects men and women, the occurrence 
increases with age. Other risk factors for PAOD include smoking, high blood, pressure, 
diabetes, and high cholesterol [5]. The buildup of plaque is referred to as atherogenesis 
and can lead to chronic ischemia-insufficient blood flow to tissues that impairs 
microcirculation function. A common symptom of PAOD is pain in the leg while doing 
physical activity; however, up to 40% of patients do not have leg pain [5]. Due to this, 
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PAOD can go undiagnosed until more serious symptoms like muscle atrophy, hair loss, 
or non-healing ulcers [25].  
 
Figure 1: Peripheral Arterial Occlusive Disease 
PAOD is the narrowing of peripheral arteries, more commonly legs than arms, due to atherosclerotic 
plaques build-up [11].  
 
Current Treatments of PAOD 
Like most diseases, early diagnosis and treatment are critical. If diagnosed early, 
dietary and lifestyle changes may reduce symptoms and halt further progression of the 
disease. Treatments also commonly include regular physical exercise, a low-fat diet, and 
smoking cessation. These changes can decrease cholesterol levels and lower blood 
pressure. Other common treatments focus on medications to manage inflammation, lipid 
levels, and prevent blood clots.  
In more serious cases, endovascular intervention such as stenting, or bypass surgery may 
be required. Endovascular treatment is a minimally invasive procedure that uses 
catheters, wires, and even stents to treat the atherosclerotic arteries (Figure 2). With 
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advances in imaging, equipment, and endovascular expertise, endovascular treatments 
have become more popular due to its outpatient nature and low cost [1].  
 
Figure 2: Stenting as an Endovascular Treatment 
A stent is guided to the atherosclerotic part of the artery using catheter. Once the closed stent is in the 
correct area the stent is expanded using a balloon. Once fully expanded, the stent is left in place to allow 
better blood flow past the compressed plaque. [20].  
 
Arteriogenesis and Vascular Remodeling 
During arteriogenesis – a body’s innate response to ischemia - endothelial and 
smooth muscle cells of existing micro vessels are stimulated to proliferate and outward 
remodeling occurs (Figure 3). This remodeling thereby enlarges natural bypasses to 
supply blood and oxygen to tissues downstream of the occluded artery. The presence of 
enlarged collaterals is a favorable prognostic factor and can increases a patient’s chances 
of recovery [3228]. Through understanding the physiology of ischemic disease, 
fibroblasts have been identified as an important therapeutic target.  
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Figure 3: Overview of Arteriogenesis 
Under ischemic conditions the body can naturally respond with arteriogenesis. A –Under normal 
conditions, existing collaterals are smaller in diameter. B – When plaque begins to build up, the pressure 
within the system changes causing an increase of stress in the collaterals. D – The changes in environment 
activate a series of events that increase the diameter of collaterals to restore the difference in pressure. [10]. 
 
Ischemic disease can cause insufficient blood flow to the brain, heart, or legs 
which can lead to stroke, myocardial infarction, or amputation due to infection, 
respectively; it is also accountable for millions of deaths worldwide. Ischemic diseases 
result from insufficient blood flow to tissues that results in necrosis, which weakens the 
heart, kills brain tissue, or peripheral tissue.  
Ischemia is not easily treated by just one gene, protein, or cell type but scientists 
have found that there are synergistic benefits to therapies that combine multiple genes, 
growth factors, or cells. After all pharmaceutical options are exhausted, stimulation of 
vessel growth is considered. There are two forms of vessel growth: angiogenesis and 
arteriogenesis. While angiogenesis refers to the formation of new capillary networks, 
arteriogenesis refers to the growth of preexisting collaterals.  
Arteriogenesis occurs when an arterial occlusion decreases downstream pressure 
and increases the shear stress in transverse collaterals. The increased shear stress 
activates endothelial cells causing an upregulation of cell adhesion molecules for 
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monocytes. The monocytes then differentiate into macrophages that secrete growth 
factors that stimulate the proliferations of endothelial and smooth muscle cells to increase 
the diameter of existing collaterals (Figure 4). 
 
 
Figure 4: Molecular Mechanism of Arteriogenesis 
Within the first 24 hours of an arterial occlusion, 1) changes in pressure increase shear stress within 
collateral arteries therefore activating endothelial cells that 2) activates signaling pathways to express 
multiple genes for monocyte attraction, activation and adhesion. The monocytes 3) are then transformed to 
macrophages that secrete growth factors to 4) stimulate smooth muscles cell proliferation [31] 
 
Previous Work Regarding Arteriogenesis 
As with many process within the body, there are a multitude of growth factors 
involved with the proliferation of smooth muscle cells (SMCs) in arteriogenesis [29]. 
Growth factors like fibroblast growth factor (FGF), transforming growth factor beta 
(TGF-B), platelet-derived growth factors (PDGF), insulin-like growth factor (IGF-I/II), 
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and monocyte chemoattractant protein-1 (MCP-1) regulate the proliferation of smooth 
muscle cells [16].  
Although the administration of isolated growth factors stimulates arteriogenesis in 
animal models, they failed in clinical trials [3]. To maximize the therapeutic benefits of 
arteriogenesis more studies are needed to determine the most effective growth factor(s), 
optimal amount of the growth factor(s), when during remodeling process to administer 
the factors, etc [13]. Since direct inject was ineffective in answering those logistical 
questions, the next wave of research began transplanting cells  that could naturally secret 
the growth factors needed for arteriogenesis [28,13]. 
Fibroblasts are a therapeutic target because they synthesize and maintain the 
matrix for vascular remodeling by controlling FGF expression [18]. Transplanted 
fibroblast-cell sheets effectively repair or promote vascular regeneration in damaged 
hearts of rats [17]. Fibroblasts and myoblasts – immature skeletal muscle cells – 
constructs promote arteriogenesis in murine hindlimb chronic ischemia models [6,9].  
 
Contractile and Kinetic Properties of Muscles 
Every muscle type has different distributions of slow- and fast-twitch muscle 
fibers; each of which produce different contractile properties and fatigue profiles. These 
different fibers contribute to differences in power – or force production – and fatigue 
properties [13]. Slow-twitch muscles are predominantly aerobic and used for endurance 
activities; fast-twitch muscles are predominantly anaerobic and used for sprinting or 
power exercise.  
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In general, force varies depending on the length of that muscle. Much like the 
elastic properties in a rubber band, increased length of muscles increases active force 
production and passive baseline tension (Figure 5). 
 
 
Figure 5: Length-Tension Relationship 
As a muscle is stretched, elastic properties increase active force production and passive baseline tension 
[13]. 
 
Muscles are categorized as fast- or slow- twitch because of differences in kinetic 
properties. Differences in fiber composition allows fast twitch muscles to reach max 
force and relax quicker than slow twitch muscles (Figure 6).  
 
 
Figure 6: Twitch Kinetics 
Fiber compositions allow fast twitch muscles to reach max force and relax quicker than slow twitch 
muscles [13]. 
 
A single stimulus produces a singular force output. Multiple stimuli – or tetanus – 
produce different force-frequency relationships in the different muscle types (Figure 7). 
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The tetanus response curve can be manipulated even further by decreasing or increasing 
the number of stimuli within a given period of time – or frequency (Figure 8). 
 
 
Figure 7: Tetanus Kinetics 
Multiple stimuli create force-frequency curves that differ significantly in shape between fast- and slow-
twitch muscles [13]. 
 
 
Figure 8: Force-Frequency Relationship 
Due to mechanical summation, an increase in frequency generally increases the amount of force production 
[13]. 
 
 In addition to force production measurements, another metric important to 
assessing muscular functionality is muscle fatigue. Fatigue occurs when there is repetitive 
stimulation over a longer period of time. Even though fast- and slow- twitch muscles 
differ on many levels, the fatigue curves produce look very similar (Figure 9). The 
quality that differentiates the two muscles types in the rate at which the force production 
decreases. More energy is needed and therefore is used quicker in fast twitch muscles 
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resulting in a faster rate of fatigue in comparison to the slower fatigue rate of slow twitch 
muscles. 
 
 
Figure 9: Fatigue Curve 
In general, force production decrease with time but the rate at which it decreases differs due to energy 
pathways and needs of the different muscle types [13]. 
 
Specific Aims 
Animals, especially rodents, are commonly used to assess numerous diseases in 
their natural progression along with the deviated progression due to novel therapeutic 
interventions. Mice are commonly used because of their convenience and 
inexpensiveness; they are small in size, can easily be housed and maintained, adapt well 
to new environments, and reproduce quickly [22]. Once a treatment is effective in-vitro at 
the cellular level, it must then be further tested to determine if its effectiveness in an 
organism.  
Considering muscle function heavily depends on the oxygen and nutrients 
transported in blood, efficient and effective vascularization is important. Muscle function 
can then be assessed using force production. Excised skeletal muscle was successfully 
tested for isometric and eccentric force duration in muscular dystrophy murine models 
using a data acquisition unit (DAQ) [23]. Muscular exhaustion – or fatigue – was tested 
 10 
in live mice using a forced treadmill protocol that measured total distance and speed at 
the point of total exhaustion occurred [19].  
Since myoblast have already been found to promote arteriogenesis, a class of 15 
students tried to assess the functional efficacy of fibroblast-collagen constructs using 
force production measurements. The fibroblast-collagen construct was statistically 
different from all groups except for the collagen-only construct. Therefore, the specific 
aim of this project is to: 
1. Repeat class experiment but improve confidence in results by decreasing 
statistical variation due to multiple operators and operating in a more 
controlled environment. 
2. Refine protocol to efficiently produce significant results given multiple 
operators and strict time restraints. 
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Chapter 2: MATERIALS AND METHODS 
Animal Housing and Care 
Male and female ICR mice along with female Swiss Webster mice were used in 
the procedures in accordance with protocols approved by the Institutional Animal Care 
and Use Committee (IACUC) of California Polytechnic State University, San Luis 
Obispo. Mice were housed in the University Vivarium and were monitored daily for 
food, water and additional enrichment factors (cage bedding, mouse house, and tunnel 
tube). 
 
Mouse Preparation 
Mice were anesthetized in an induction chamber using 5% isoflurane in oxygen 
flowing at 3-5 l·min-1. They were then subcutaneously administered buprenorphine 
analgesic (0.075 mg·kg-1). After the initial anesthetization, mice were transferred to a 
heating pad on a surgical slate and administered 1-3% isoflurane flowing at 0.8-1.0 l· 
min-1 through a nose cone. The heating pad was set to maintain a core body temperature 
of 35oC for the duration of the procedure using a rectal temperature probe. The hair on 
the lower, ventral region of the mouse was removed prior to surgery with trimming 
clippers and depilatory cream. Veterinary ointment was then applied to the corneas to 
prevent desiccation. The entire mouse preparation protocol can be seen in Appendix A. 
 
Femoral Artery Ligation 
To model peripheral arterial occlusion (PAO), a femoral artery ligation was 
performed in the hindlimb of a murine animal model. The entire procedure was 
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performed under aseptic conditions to reduce contamination and infections. The initial 
incision was made on the medial potion of the thigh and stopped at the abdominal wall 
(Figure 10A). Using blunt dissection, surrounding connective tissue was removed and 
the epigastric fat pad was retracted and reveal the neurovascular bundle. Connective 
tissue above the bundle was gently removed to isolate the femoral artery; once it was 
isolated 6-0 silk suture was used to ligate the femoral artery between the epigastric and 
popliteal branches (Figure 10B). The entire femoral artery ligation protocol can be seen 
in Appendix A. 
 
    
Figure 10: Femoral Artery Ligation. 
A – The initial incision was made on the medial aspect of the femur to the abdominal wall to expose the 
epigastric fat pad and neurovascular bundle. B – The femoral artery was ligated between the epigastric and 
popliteal branches. 
 
Fibroblast Construct Transplantation and Suture 
A premade pocket under the gracilis anterior muscle was created using blunt 
dissection to house the collagen construct. The entire construct was then gently placed 
beneath the muscle (Figure 11A). To prevent desiccation the entire surgical site was 
irrigated with sterile phosphate buffered saline (PBS). The incision was then closed using 
7-0 polypropylene monofilament suture (Figure 11B). The mouse was then 
A) B) 
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subcutaneously administered buprenorphine analgesic (0.075 mg·kg-1) again. Mice were 
then returned to the University Vivarium to be monitored daily using ambulation scoring 
until walking normally. The entire femoral artery ligation protocol can be seen in 
Appendix A. 
 
    
Figure 11: Fibroblast Construct Transplantation.  
A – The entire fibroblast construct was gently tucked under the gracilis muscle. B – The surgical incision is 
then sutured closed. 
 
The surgical groups used for this study can be found in Table 1 below. Surgical 
group 1 consisted of mice that were ligated and blunt dissected under the gracilis muscle 
but did not receive a construct. Surgical group 2 consisted of mice that were ligated and 
blunt dissected to receive a construct with no fibroblasts. Surgical group 3 consisted of 
mice that were ligated and blunt dissected to receive a construct with fibroblasts.   
 
Table 1: Experimental Design and Surgical Groups 
Surgical Groups Number of Mice Description 
1 4 Ligated, Dissected, no construct 
2 5 Ligated, Dissected, construct with no cells 
3 5 Ligated, Dissected, construct with 
fibroblasts 
 
A) B) 
 14 
Force Production and Gracilis Muscle Harvest 
 Seven days post-surgery, arteriogenesis was functionally tested using force 
production measurements as seen in Appendix B. This was achieved using blunt 
dissection to dorsally reflect the sciatic nerve, which was stimulated to contract the 
gracilis muscle (Figure 12A). Once the nerve was reflected using parafilm, a curved 
current electrode was attached. Then the Achilles tendon is exposed and silk suture is tied 
to the end of the tendon (Figure 12B and Figure 12C). The suture is used to connect the 
Achilles to a force transducer (Protocol in Appendix C). Measurements were taken for 
force-intensity, force-frequency and fatigue. 
 
       
Figure 12: Force Production Set-Up.  
A – The sciatic nerve is reflected using parafilm for ease of access. B – The Achilles tendon is then 
exposed and silk suture is knotted to the end so it can be connected to the force transducer. C – The whole 
force production set up is constructed to quantitatively measure an aspect of arteriogenesis. 
 
 Once measurements were taken, sodium nitroprusside (SNP) was applied to the 
gracilis muscle to induce maximal vasodilation. After maximal dilation, the gracilis was 
fixed in-situ for 15 minutes using paraformaldehyde (4% PFA) and covered with plastic 
wrap to prevent desiccation. After fixation, the muscle was removed from surrounding 
tissue and placed in more PFA overnight at 4oC. Once 24 hours have passed, they were 
washed using and store in PBS at 4oC until stained.  
 
A) B) C) 
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Staining and Imaging  
 Alpha smooth muscle-actin (-SMA) was used to stain and visualize the 
collateral network throughout the muscle. A working solution of -SMA (1:200) was 
prepared along with saponin (0.1%) and bovine serum albumin (BSA, 2%) in PBS. The 
muscle was incubated in the stain for 3 nights. After the staining period, they were 
washed in a saponin (0.1%) and PBS mixture three times and in PBS once. Finally, they 
were mounted on glass slide. This staining protocol is in Appendix D. 
 A widefield fluorescent microscope was sued to visualize and image the muscle 
using 550nm excitation and 570nm emission. Images of the stem, midzone, and re-entry 
were captured at 4x or 10x magnification. Gracilis imaging protocol is in Appendix E. 
 
Data and Statistical Analysis 
 The Data Pad function in Lab Chart Reader was used to obtain force production 
and integral measurements and then exported to Microsoft Excel according to the 
protocol in Appendix F. Microsoft Excel was then used to graphically display data while 
ImagesJ was used to measure vessel diameters. Differences in force production, force 
intensity, and fatigue along with percent change in diameter were determined by 
ANOVA tests, a p<0.05 was used to indicate significance.
 16 
Chapter 3: RESULTS 
 The potential functional contribution of fibroblasts was tested by transplanting 
fibroblast-containing collagen constructs into a mouse model with a ligated femoral 
artery. The three groups tested were: ligated with no construct in the pocket, ligated with 
collagen construct in the pocked, and ligated with a fibroblast-containing collagen 
construct in the pocked. Force production measurements were taken regarding 
stimulation intensity, stimulation frequency, and fatigue, and results are presented below. 
The control group consists of the non-ligated leg of each mouse.  
 
Force-Intensity 
 In general, across all treatment groups, force production increased with increased 
stimulation intensity (Table 2). Overall, the pocket group was lower than the collagen 
and fibroblast groups (Figure 13). With regards to various stimulation intensities, the 
control group was greater than the pocket group between 0.75 and 4.5 mV.  
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Table 2: Muscle Force Production with Increasing Intensity 
Intensity 
(mV) 
Force Production (mN/mg) 
Pocket Collagen Fibroblast Control 
0.25 0.04 + 0.04 0.06 + 0.04 0.00 + 0.00 0.18 + 0.10 
0.50 0.06 + 0.06 0.24 + 0.14 0.29 + 0.27 0.54 + 0.14 
0.75 0.16 + 0.11 0.49 + 0.24 0.54 + 0.39 0.94 + 0.11 
1.00 0.28 + 0.15 0.67 + 0.33 0.59 + 0.38 1.06 + 0.10 
1.25 0.36 + 0.16 0.75 + 0.37 0.69 + 0.36 1.14 + 0.10 
1.50 0.43 + 0.16 0.77 + 0.37 0.79 + 0.36 1.17 + 0.11 
1.75 0.46 + 0.17 0.77 + 0.35 0.83 + 0.36 1.20 + 0.13 
2.00 0.48 + 0.17 0.78 + 0.34 0.86 + 0.35 1.17 + 0.15 
2.25 0.50 + 0.18 0.83 + 0.32 0.93 + 0.34 1.21 + 0.12 
2.50 0.52 + 0.18 0.89 + 0.30 0.98 + 0.33 1.28 + 0.13 
2.75 0.54 + 0.18 0.93 + 0.29 1.00 + 0.33 1.30 + 0.13 
3.00 0.56 + 0.19 0.97 + 0.29 1.03 + 0.32 1.34 + 0.12 
3.25 0.59 + 0.19 1.01 + 0.28 1.10 + 0.35 1.31 + 0.10 
3.50 0.59 + 0.19 1.05 + 0.28 1.08 + 0.33 1.38 + 0.12 
3.75 0.62 + 0.19 1.08 + 0.30 1.07 + 0.34 1.43 + 0.12 
4.00 0.64 + 0.19 1.04 + 0.28 1.06 + 0.34 1.45 + 0.12 
4.25 0.59 + 0.19 1.07 + 0.27 1.05 + 0.35 1.51 + 0.13 
4.50 0.63 + 0.19 1.18 + 0.34 1.04 + 0.34 1.47 + 0.12 
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Figure 13: Muscle Force Production with Increasing Intensity 
Force produced in measured for twitch recruitment of four sub-groups at increasing stimulation intensities: 
.25, .50, .75, 1.00, 1.25, 1.50, 1.75, 2.00, 2.25, 2.50, 2.75, 3.00, 3.25, 3.50, 3.75, 4.00, 4.25, and 4.50 mV. A 
–  Raw data trace of force production using a data acquisition unit that stimulated the sciatic nerve and 
measured force using a force transducer attached to the Achilles tendon of a mouse. B – Averaged 
normalized muscle force production, using individual gastrocnemius weights, for each treatment group at 
increasing stimulation intensities (n=14 control, n=4 pocket, n=5 collagen, and n=5 fibroblasts). Data are 
presented as mean ± SE. * denotes p < 0.05 for pocket vs collage/fibroblast vs control and ** denotes p < 
0.05 for pocket vs control at 0.75mV to 4.5 mV.  
 
Force-Frequency 
 In general, the control group and the fibroblast group were greater than pocket 
group (Table 3). In most cases the stimulation frequency of 50 Hz produced the greatest 
force production; excluding the collagen group which had higher force production in the 
5Hz and 10 Hz frequency groups (Figure 14). At 50 Hz stimulation frequency only the 
fibroblast group was significantly greater than the pocket group. At 2.5 Hz and 5 Hz 
stimulation frequency, only the control group was significantly greater than the pocket 
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group. In all the other stimulation frequency categories, no significant difference was 
found among the groups. 
 
Table 3: Muscle Force Production with Increasing Frequency 
Freq. 
(Hz) 
Force Production (mN/mg) 
Pocket Collagen Fibroblast Control 
2.5 0.64 + 0.20 1.34 + 0.49 1.25 + 0.39 1.80 + 0.15 
5.0 0.68 + 0.21 1.33 + 0.48 1.26 + 0.40 1.80 + 0.16 
10.0 0.67 + 0.21 1.03 + 0.34 1.34 + 0.33 1.25 + 0.22 
20.0 0.69 + 0.21 1.07 + 0.42 1.45 + 0.33 1.31 + 0.24 
50.0 1.02 + 0.47 1.29 + 0.52 2.34 + 0.63 1.88 + 0.40 
 
  
 
 
Figure 14: Muscle Force Production with Increasing Frequency 
Force produced in measured for twitch recruitment of four sub-groups at increasing stimulation 
frequencies: 2.50, 5.00, 10.00, 20.00, and 50.00 Hz. A – Raw data trace of force production using a data 
acquisition unit that stimulated the sciatic nerve and measured force using a force transducer attached to the 
Achilles tendon of a mouse. B – Averaged normalized muscle force production, using individual 
gastrocnemius weights, for each treatment group at increasing stimulation frequencies (n=14 control, n=4 
pocket, n=4 collagen, and n=4 cells). Data are presented as mean ± SE. * denotes p < 0.05 for pocket vs 
fibroblast/control, ** denotes p < 0.05 for pocket vs control at 2.5 Hz, # denotes p < 0.05 for pocket vs 
control at 5.0 Hz, and ## denotes p < 0.05 for pocket vs fibroblast at 50 Hz. 
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Fatigue 
Overall, pocket was found to have the smallest integral and shortest half-time 
(Table 4: Muscle ). With regards to integrals, the collagen group was found to be 
significantly greater than the pocket group. No significant difference was found regarding 
time to half maximum force production (Figure 15).  
 
Table 4: Muscle Fatigue - Time to Half and Integral of Maximum Force Production 
Surgical Group Pocket Collagen Fibroblast Control 
Abs. Integral 
(mV/s) 
17.48 + 10.78 60.90 + 7.64 45.94 + 10.72 44.17 + 8.14 
Time to Half 
(s) 
6.31 + 3.29 11.81 + 3.27 13.45 +  5.60 11.47 + 3.65 
 
 
 
 
 
Figure 15: Time to Half and Integral of Maximum Force Production 
Force produced in measured using maximum stimulation intensity and frequency for 30 seconds. The time 
it takes to go from maximum force production to half of that is also show. A – Raw data trace of force 
production using a data acquisition unit that stimulated the sciatic nerve and measured force using a force 
transducer attached to the Achilles tendon of a mouse. B – Averaged normalized muscle force production, 
using individual gastrocnemius weights, for each treatment group at (n=9 control, n=2 pocket, n=3 
collagen, and n=4 cells). Data are presented as mean ± SE. * denotes p < 0.05 for pocket vs collagen with 
regard to absolute integral. 
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Overall, the collagen and control groups have a smaller percent change than the 
fibroblast group which was smaller than the pocket group (Table 5).  With regard to the 
control, fibroblast, and collagen groups, the rate of percent change was similar before 10 
second and then leveled off at differing rates (Figure 16). 
 
Table 5: Percent Change in Fatigue Force Production 
Time (s) 
Force Production (%) 
Pocket Collagen Fibroblast Control 
0 100.0 + 0.0 100.0 + 0.0 100.0 + 0.0 100.0 + 0.0 
1 79.2 + 15.7 89.6 + 3.9 83.8 + 2.2 73.2 + 5.8 
2 69.5 + 26.2 84.0 + 4.4 80.2 + 5.0 70.2 + 5.8 
3 60.7 + 34.0 77.8 + 5.4 75.5 + 8.0 66.5 + 5.3 
4 56.4 + 33.8 71.2 + 6.9 70.6 + 10.5 62.6 + 4.7 
5 51.8 + 33.2 64.4 + 8.1 65.7 + 11.3 57.9 + 4.4 
6 48.2 + 30.3 58.8 + 9.6 60.9 + 11.5 54.0 + 4.4 
7 42.0 + 27.5 54.3 + 10.5 56.0 + 11.1 51.1 + 4.6 
8 36.0 + 23.4 50.7 + 11.1 51.2 + 10.9 49.3 + 4.7 
9 31.3 + 20.5 48.2 + 11.6 47.7 + 11.1 48.0 + 4.9 
10 28.3 + 18.3 46.1 + 11.5 45.0 + 11.1 46.8 + 5.1 
11 25.2 + 16.6 45.1 + 11.0 36.9 + 7.1 45.7 + 5.3 
12 21.9 + 14.8 44.1 + 10.5 33.9 + 6.7 45.0 + 5.5 
13 19.7 + 13.2 43.1 + 9.9 34.3 + 8.6 44.4 + 5.6 
14 17.5 + 11.8 42.2 + 9.3 33.5 + 10.0 44.1 + 5.6 
15 16.5 + 10.1 41.2 + 8.7 31.4 + 10.3 43.6 + 5.6 
16 14.5 + 9.8 39.9 + 8.4 30.0 + 10.7 43.3 + 5.5 
17 12.9 + 8.8 38.9 + 7.9 28.6 + 11.2 42.7 + 5.6 
18 11.8 + 7.9 40.7 + 4.5 26.7 + 11.2 41.8 + 5.5 
19 10.6 + 7.4 40.1 + 3.5 24.4 + 11.1 41.1 + 5.6 
20 9.7 + 6.7 38.4 + 3.2 23.8 + 11.1 40.4 + 5.7 
21 8.5 + 6.4 37.3 + 2.8 23.1 + 11.6 39.4 + 5.7 
22 7.7 + 5.9 35.8 + 2.7 22.3 + 12.4 38.7 + 5.8 
23 6.6 + 5.8 34.5 + 2.5 21.6 + 12.5 37.8 + 5.8 
24 6.1 + 4.8 32.8 + 2.9 20.5 + 12.9 36.9 + 5.7 
25 5.2 + 4.1 31.7 + 2.9 20.0 + 13.2 36.1 + 5.7 
26 4.4 + 3.8 30.2 + 3.1 24.5 + 17.4 35.4 + 5.8 
27 3.7 + 3.3 29.2 + 3.1 23.8 + 16.9 34.7 + 5.7 
28 3.1 + 2.9 28.1 + 2.9 23.4 + 17.3 34.1 + 5.8 
29 2.6 + 2.6 26.9 + 3.2 23.1 + 17.5 33.4 + 5.8 
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Figure 16: Percent Change in Fatigue Force Production  
Force produced in measured using maximum stimulation intensity and frequency for 30 seconds. The 
percentage is calculated using the average force production in the given time window divided by the max 
force production in the 0 to 1sec time interval. A – Raw data trace of force production using a data 
acquisition unit that stimulated the sciatic nerve and measured force using a force transducer attached to the 
Achilles tendon of a mouse. B – Percent change in force production over a 30sec time interval (n=9 control, 
n=2 pocket, n=3 collagen, and n=4 cells). Data are presented as mean ± SE. * denotes p < 0.05 for pocket 
vs myoblast vs collagen/control. 
 
Profunda Femoris Diameter  
Overall, the collagen and fibroblast groups had the largest percent change in 
diameter in the midzone (Table 6). Although the fibroblast group saw largest change in 
diameter in each zone it was not statistically significant from the other surgical groups 
(Figure 17). In the midzone, the fibroblast group was greater than the pocket group.  
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Table 6: Percent Change in Diameter of Collateral Networks 
Surgical Group Reentry Midzone Stem 
Pocket 19.4 + 5.6% 14.3 + 7.2% 31.6 + 8.8% 
Collagen 22.6 + 9.0% 38.1 + 10.1% 35.3 + 6.8% 
Fibroblast 35.2 + 6.4% 46.6 + 14.1% 38.4 + 8.0% 
 
           
 
Figure 17: Percent Change in Diameter comparing Surgical Groups 
Diameters for each zone in the collateral network was compared within each surgical group with respect to 
their control. A – Raw photo of the Profunda or stem zone at 4x magnification. B – Raw photo of the 
midzone at 10x magnification. C – Raw photo of the Saphenous or reentry zone a 4x magnification. D – 
Percent change in diameter for each surgical group with respect to their control (n=15 control, n=4 pocket, 
n=5 collagen, and n=6 cells). Data are presented as mean ± SE. * denotes p < 0.05 for pocket vs fibroblast 
in the midzone. 
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Chapter 4: DISCUSSION 
Clinical Significance 
Since PAOD is a chronic disease with general symptoms that disproportionately affect an 
already vulnerable group – the elderly – it is a challenging disease to address. Even though 
exercise is effective in prolonging the disease’s onset, this disease can also make it painful to 
exercise. Other options include oral vasoactive compounds and surgical stenting [26]. Oral 
vasoactive compounds are cheap but can have secondary side effects that require close 
monitoring. Stenting is a more invasive treatment and carries the dangers of inserting synthetic, 
foreign materials in to the body.  
These results from this study proposes another treatment by localizing arterial remodeling 
and using materials made by the body. The transplantation of fibroblast-containing collagen 
constructs under collateral networks of ligated mice was found to promote collateral enlargement 
in the midzone. Though this study found that collagen constructs functionally improves muscle 
force production with regard to intensity and frequency, it was not able to differentiate between 
collagen-only constructs and fibroblast-containing collagen constructs.  
 
Future Work 
 Since the 1980s, previous research focused on characterizing the factors contributing to 
arteriogenesis [2]. The research in the past couple decades have tested those factors as single 
growth factors and have transplanted cells that are known to secrete those factors, to determine 
which ones are more effective or how much is needed to be effective [27]. The next wave a 
research is to assess the functionality of all these treatments. One of the first functionality 
assessments tested muscular exhausting or fatigue using a treadmill.  
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More recent studies use DAQs to obtain muscle force production measurements. Starting 
in the early 2010s, muscles were excised, stored in specialized solutions, and connected to two 
force transducers to measure force production [23,30]. It was only in the past few years that 
studies have directly attached the mouse to DAQs and electrically stimulated them to obtain 
force production measurements to assess cardiovascular disease [7].  
DAQ set-ups inherently allow more consistency in data collection than observational 
studies and therefore it can decrease some variability. This study in particular, has demonstrated 
the utility in assessing the functional viability for therapeutic treatments. It not only compares the 
proposed treatment to the disease state without treatment but it can also produce control or non-
disease state results. Furthermore, multiple metrics for muscle functionality –force production, 
force intensity and fatigue – can comfortably and accurately be tested within one session, unlike 
some previous methods. Since excising a muscle can cause damage and affect data, it is safer to 
excise it after collecting force production measurements.  
 
Limitations 
 Considering the complexity of this study there were many logistical limitations that 
resulted in variations in many external factors.  
First, to keep this project manageable, constructs were made by students whose focus 
were to create the collagen constructs. Due to this, surgeries were scheduled around when 
constructs could be made; this resulted in non-randomized data collection. Also, due to previous 
commitments of other students, the constructs had to made by multiple people.  
Additionally, considering how many projects were going on at the time, the mouse 
selection was first-come, first-serve. This resulted in two mice types being used: Swiss Webster 
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and colony mice. Inherently, the colony mice have more variation and contained both male and 
female mice while the Swiss Websters’ were only female. Sex influences the vascular response 
due to impaired vasodilation [8]. 
 
Procedural Improvements 
After performing the protocol numerous times, there are many tips and reminders to 
ensure an effective and efficient data collection session. The biggest suggestion would require 
operators to familiarize themselves with contractile and kinetic properties of muscle to 
understand why these metrics are used and recognize the results produced [13].  
Throughout the study, the one error that created the longest delay is the slippage of the 
suture connecting the muscle to the force transducer. In order to prevent the suture from slipping 
off the Achilles tendon, cut the tip of the calcaneus to hold the suture knot in place. To prevent 
the suture from slipping out of the force transducer, use a hook- rigging mechanism instead of 
the clamp mechanism used now. This could be achieved by knotting the open end of the suture to 
create a loop that can be secured to a hook rather than pinched between clamp.  
After analyzing force-intensity production data many intensity intervals were found to be 
redundant (see Appendix G). In order to save time collecting and analyzing the data, the 18 
intervals at 0.25mV increments can instead be cut in half by stimulating every 0.5 mV from 
0.5mV to 4.5mV. 
Previous research indicates that the gastrocnemius muscle consists mostly of fast-twitch 
muscle fibers [13]. This suggest data obtain would more closely resemble that of an EDL 
muscle. Previous research has found that EDL-like muscles have a very unique force-frequency 
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curve (Figure 18). Considering this, less points before 10 Hz and more points between 15Hz and 
30 Hz can better predict the force-frequency relationship in the gastrocnemius muscle.  
 
Figure 18: Force Frequency Curve of EDL Muscle 
Considering the gastrocnemius muscle is mostly composed of fast twitch muscles it most likely that its force-
frequency curve will resemble that of the EDL [13].  
 
With regard to fatigue, the most difficult task was identifying a way to intuitively present 
and accurately analyze the data. No statistically significant differences or trends were found in 
comparing area under the curve nor time to half of the max force. An educational active learning 
protocol effectively depicted fatigue as a percentage of decline force over a period of time 
(Figure 19). By taking an average of force production, in bin sizes of a second, from 0s to 30s of 
the fatigue data collect a more intuitive graph can be depicted and more accurate statistics can be 
taken. 
 28 
 
Figure 19: Rate of Force Production During Fatigue 
Maximum force production declines with time. Slow twitch muscles decline at a slower rate than fast twitch muscles 
[13]. 
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APPENDIX 
Appendix A: Restraint, Ligation, and Suturing Protocol for Arteriogenesis in a Mouse 
Model 
 
 
 
1.0 PURPOSE 
This protocol serves as a reference checklist to perform a surgical modification to a 
mouse model of peripheral arterial occlusion (PAO) and deliver a cell therapy to 
promote arteriogenesis by 1) properly restraining and intraperitoneally injecting 
anesthetic to minimize trauma and pain, 2) skillfully performing a skin incision under a 
stereomicroscope to minimize amount of stitches needed, 3) ligating the femoral artery 
to model PAOD, 4) inserting a cell therapy construct to promote arteriogenesis and 5) 
accurately suturing the incision to reduce infection. 
2.0 Equipment
• Stereomicroscope 
• Gloves (2 sets) 
• Hot pack 
• Bench covers  
• Spray bottle of 70% 
isopropyl alcohol (IPA) 
• Spray bottle of 
Nolvasan 
• Syringe (1ml/10ml)  
• Surgical tape  
• Gauze Sponges (4x4 
& 2x2)  
• Surgical drapes 
(20x20 & 16x20) 
• Depilation cream 
(Veet) 
• Ophthalmic ointment 
• Cotton Swabs 
• Standard pattern 
forceps 
• Curved iris scissors 
• Dumont #7 forceps 
• Needle holders 
• Prolene 7-0 Blue 
monofilament suture 
• C-1 13 mm 3/8 taper 
suture needle 
• Silk suture (1-2 
inches) 
• Cell therapy construct 
• Retractor 
•  Autoclave tape
3.0 Methods 
3.1 Basic Rules 
a. Always set down forceps and scissors with tips up. 
b. Hold instruments in any way to perform movement without contorting body and 
compromising stability. 
c. Maximize exposure and minimize trauma. 
d. Keep back straight/good posture to get through long surgeries. 
e. Saline. Saline. Saline. When you pull head out of scope, add saline. 
f. Do not go over sterile fields. 
3.2 Sterilized Instruments 
 Surgical drape (18-20inches 
square). 
 Use autoclave tape to close tray 
and wrap. 
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3.3 Sterile pack 
 Prolene suture 
 Silk ligature 
 3 4x4 gauze sponge 
 4 cotton swabs  
 surgical drape 16x20inches 
3.4 Open and activate hot pack 
 Weight mouse _______grams 
3.5 Scruff Restrain and Injection 
 Grab base of mouse’s tail with dominant hand. 
 With fingertips (thumb & index) pinch scruff with 
non-dominant hand. 
 Invert: pinch base tail with ring finger and use 
middle finger to support its back.  
 Angle animal/nose downward. 
 Insert needle at a 30o angle (bevel side up) 
(Figure 1a).  
 Pull back on syringe to confirm vacuum.  
 IP inject fluid/anesthesia. SubQ inject analgesia. 
 Paw pinch.  
3.6 Depilation 
 Tape down mouse’s feet on 4x4 sponge gauze. 
 Rub cream going against the grain (Figure 1b).  
 Let rest for a couple minutes. 
 Remove with gauze sponge. Remove excess off 
with Nolvasan. 
 Paw pinch. 
 Apply eye ointment and punch ear hole.  
 Move to fresh bench cover (heating pad). 
3.7 Sterile set up 
 Open sterile tray away from bench 
cover. 
 Open and dump contents of sterile 
pack. 
 Wash hand up to elbow with 
disinfectant soap 
 Put on isolation mask and cap. 
 Put on sterile gloves.  
 Prep saline dish. (ask partner) 
 Move and put sterile drape over 
mouse up to front paws. 
 Cut small window. Feel for hind 
limb. 
Figure 1: Area of a) needle insertion-green 
and b) depilation cream application-red. 
 
Figure 2: Incision above neurovascular 
bundle to abdominal wall. (Note: this cut can 
be made smaller than as seen in the picture.)  
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3.8 Skin Incision  
 Tent skin with standard pattern forceps. 
 With iris scissors, cut incisions perpendicular to 
tented skin and above femoral vein and artery. 
 Keep cutting until past epigastria fat pad near the 
abdominal wall (~1 cm), see Figure 2.  
 Blunt dissect connective tissue using Dumont #7 
forceps. 
3.9 Ligation 
 Blunt dissect to move epigastric fat pad. 
 Gently remove connective tissue over 
neurovascular bundle.  
 Separate artery from vein. 
 Note: Be aware of landmarks (Figure 3). 
 Ligate upstream from popliteal and 
downstream from the epigastric. 
 Isolate artery with silk suture. 
 Tie off artery (2 knots). 
3.10 Gracilis Pocket (Cell therapy construct) 
 Lightly jiggle muscle to see gracilis separation 
 Grab muscle gently at top margin.  
 Blunt dissect just underneath muscle. 
 Create small pocket for construct. 
 Reflect back pocket and carefully stuff collagen gel 
underneath adductor muscle: see Figure 4 
3.11 Suturing  
DO NOT OVER TIGHTEN 
 Using graph forceps pull skin back push suture through skin locked needle holders. 
 Surgeon square knot at bottom end of incision (6 knots). 
 Spiral sutures up the length of incision. 
 Instrument square knot (6 knots) 
 Cut off excess suture; see Figure 5 for final product.  
Figure 3: Landmarks of the neurovascular bundle. 
Figure 4 Gracilis pocket landmarks for the cell therapy 
construct. 
Figure 5 Final product of all three knot types.  
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Date__________  Hindlimb Ischemia Surgery - Resection   Initials ________ 
Mouse Information 
Mouse Information 
DOB: ______________________ 
Sex: _______________________  
Tag: _______________________ 
Genotype/strain: _____________ 
Cage: ______________________ 
 
Materials 
Sterilize- autoclave or flash autoclave 
____1. forceps (2) 
____2. fine forceps (2) 
____3. ultrafine forceps (1) 
____4. fine scissors (1) 
____5. microscissors spring loaded (1) 
 
Pre-sterilize in autoclave 
____6. cotton gauze (2) 
____7. cotton swabs (12) 
____8. 6.0 silk suture (2 x 1-inch) 
____9. needle holder (1) 
 
Obtained in surgery suite 
____10. sterile Petri dish w/ sterile saline 
____11. sterile gloves 
____12. sterile 7.0 prolene suture 
____13. heat-cautery 
____14. FST heat pad w/ rectal probe 
____15. heat pad 
____16. recovery bin & weigh boat 
____17. depilatory cream 
____18. non-sterile cotton swabs 
____19. non-sterile cotton gauze 
____20. isolation mask & cap 
____21. analgesic (Buprenorphine) 
 
Surgery preparation 
____22. Spray surgery area with Nolvasan 
____23. Weigh animal in weight boat 
____24. Place animal in anesthesia box 
____25. Open the oxygen cylinder and set anesthesia-
machine flow meter to ~3 l·min-1 
____26. Anesthetize animal w/ 5% isoflurane  
____27. Affix non-rebreathing circuit to bench-top with 
tape  
____28. Reduce flow rate to 0.5-1.0 l·min-1 and the 
isoflurane to 1-3% 
____29. Apply ear tag high on left ear 
____30. Lay animal supine with nose in nose-cone 
____31. Shave hair on the right hindlimb & lower 
abdomen with clippers  
____32. Remove excess hair with depilatory cream 
____33. Spray right hindlimb with Nolvasan 
____34. Return animal to anesthesia box 
____35. Apply 4x4 gauze sponge to heat pad to protect 
animal from excessive heat 
____36. Affix non-rebreathing circuit to surgery table w/ 
chemistry clamp 
 
____37. Lay animal supine on circulating heat pad w/ 
nose in nose-cone 
____38. Insert rectal probe and set thermo-controller to 
37°C 
____39. Apply veterinary ointment to eyes to avoid 
drying during procedure 
____40. Apply veterinary ointment to anus and place 
rectal probe ~1cm into anus to monitor core-
body temperature 
 
Surgery 
____41. Make a small incision on the middle, medial 
aspect of the left thigh 
____42. Extend the incision up to the abdominal wall  
____43. Blunt dissect the subcutaneous connective tissue 
to maximize surgical exposure 
____44. Use cautery to remove fat pad overlying femoral 
a-v pair & cauterize epigastric a-v pair 
____45. Blunt dissect the femoral artery-vein pair from 
the nerve starting just upstream to the muscular 
branch & extending to half-way between the 
knee & ankle 
____46. Tie off the saphenous a-v pair with 6.0 silk 
suture, halfway between the knee & ankle 
____47. Tie off the femoral a-v pair with 6.0 silk suture, 
halfway just upstream to the muscular branch 
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____48. Grasping the distal ligature, use the cautery & 
microscissors to remove the a-v pair up to the 
upstream ligature 
____49. Gently rest cotton swabs on hemorrhage sites 
____50. Use 6.0 polypropylene suture to close the skin  
____51. Make a small incision on the middle, medial 
aspect of the right thigh 
____52. Extend the incision up to the abdominal wall  
____53. Blunt dissect the subcutaneous connective tissue 
to maximize surgical exposure 
 
Post-Surgical  
____54. Give the animal an subcutaneous injection of 
buprenorphine (0.075mg/kg) 
____55. Place the animal in the recovery bin, on a blue 
bench cover, above a heat pad and allow to 
recover 
____56. Turn flow meter down to 0, turn off isoflurane, 
and close the oxygen cylinder 
____57. Indicate surgery on cage card  
 
Notes 
 _____________________________________________ 
 _____________________________________________ 
 _____________________________________________ 
 _____________________________________________ 
 _____________________________________________ 
 _____________________________________________ 
 _____________________________________________ 
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Appendix B: Force Production and Atrophy of the Gastrocnemius and Immunohistology of 
the Gracilis Muscle 
 
 
1.0 PURPOSE 
This protocol serves as a reference checklist to assess the efficacy of treating a ligated 
artery mouse with the fibroblast cell construct by 1) dissecting and reflecting the sciatic 
nerve for ease of stimulation of a muscle contraction and gently dissecting the Achilles 
tendon to measure muscle force production of the gastrocnemius muscle, and 2) 
removing the gracilis to stain and assess artery growth, and 3) removing the 
gastrocnemius muscle to weigh and evaluate muscle atrophy.  
2.0 Equipment 
• Depilation cream 
(Veet) 
• Cotton Swabs 
• Saline 
• Gauze Sponges (4x4 
& 2x2)  
• Stereomicroscope 
• Standard pattern 
forceps 
• Curved iris scissors 
• Parafilm (1/8”-1/4” 
strip) 
• Silk suture (1-2 
inches) 
• Force transducer set 
up 
• Plastic cab tie 
• Curved electrode 
(current mA) 
• Surgical tape  
• Power lab/Laptop 
• Paraformaldehyde 
• Spray bottle of 
Nolvasan  
• Spray bottle of 70% 
isopropyl alcohol (IPA) 
• Syringe (1ml/10ml)  
• Dumont #7 forceps 
• Retractor 
3.0 Methods 
3.1 Depilation 
 Lay mouse on stomach and tape. 
 Apply Veet on the left side (medial and 
laterally/dorsal and ventral). 
3.2 Sciatic Dissection 
 Lay stomach down (dorsal) 
 Make incision hip and knee.  
 Blunt dissection tissue using scissors.  
 Cut laterally to maximize exposure and find triangle of adipose (Figure 1). 
 Lift up adipose with #7 forceps and blunt dissect gap. 
Figure 1: Area of adipose to lift 
up. 
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 Look for sciatic nerve (white) – clearly visible 
outside of scope too.  
3.3 Sciatic Reflection 
 Grab parafilm strip. 
 Place forceps under nerve from the top and grab 
parafilm. 
 As seen in Figure 2. 
 Apply saline then cover with plastic wrap. 
3.4 Achilles Dissection 
 Using graph forceps and iris scissors make skin 
incision right above heel. 
 Gently blunt dissect and cut with iris scissors. 
 Cut of skin to improve visibility. Go farther than 
heel.  
 Blunt dissect with #7 forceps. 
 Tie suture (2x) around tendon (see Figure 3). 
 Do NOT cut until connected to force transducer. 
3.5 Force Transducer Setup (see Figure 4) 
 Place mouse stomach up. 
 Use cable to attach hind paw to cross bar. 
 Grab suture with standard patterns. 
 Attach suture to force transducer and cut 
tendon with iris scissors.  
 Using #7 pull sciatic nerve to wrap hook 
electrode around it. 
 Tape down end of electrode. 
 Connect VNC cable to top output port (+). 
 Hook up PowerLab (as in 460) 
3.6 Transducer Optimization 
 Center pinhole of transducer has to be right 
above Achilles and gastrocnemius. 
 90o angle in all planes. 
 Electrode  PowerLab  Computer  Lab 
Chart 
Figure 2: Reflected sciatic nerve with 
parafilm  
Figure 3: Achilles tendon with  
suture placement. 
Figure 4: Force Transducer 
set-up and optimization. 
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3.7 Gracilis Exposure 
 Place stomach up on surgical stage. 
 Make incision (is same place as ligation).  
 Extend using iris scissor blunt dissection. 
 Blunt dissect fat pad out of way. 
 Apply paraformaldehyde on gracilis muscle. 
 Cover with plastic crap. 
 Let sit for 20 minutes. 
3.8 Gracilis Dissection Excision (anterior) 
 Use gauze sponge to pick up extra 
paraformaldehyde fixative.  
 Start dissecting near gracilis pocket top. 
 “Tunnel” above and below gracilis to free the whole muscle. 
 Blunt dissect under the anterior gracilis. 
 Blunt dissect outside saphenous and profunda. 
Note: Do NOT go deep. Gracilis anterior is fairly thin. 
 Cut muscle with iris scissors outside of saphenous and 
profunda (Figure 5). 
 Put muscle in centrifuge tube for post fixation. 
3.9 Gastrocnemius Dissection Excision 
 Cut off skin between Achilles and gracilis to expose 
gastrocnemius. 
 Can just peel away from hind limb using tendon. 
 Cut adductor muscle on top of gastrocnemius. 
 Blunt dissect and cut using iris scissors to separate muscle. (See Figure 6).  
 Weight.  
  
Figure 5: Gracilis dissection excision 
landmarks. 
Figure 6: Separated 
Gastrocnemius muscle. 
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Appendix C: PowerLab Optimization Protocol 
 
 
Required Equipment 
• LabChart 7 software 
• PowerLab Data Acquisition Unit 
• Bridge Pod  
• Force Transducer  
• Small weight between 5–50 grams 
• Manipulator/Micropositioner and clamps 
• Ring stand 
• Chemistry clamp 
• Silk suture 
• Petri dish 
• One mouse  
• Saline 
• Small millimeter ruler 
• Tape 
• Muscle Stimulation Equipment 
• Vascular Clamp 
Procedure 
Equipment Setup and Calibration 
1. Make sure the PowerLab is turned off and the USB cable is connected to the computer. 
2. Connect the Force Transducer cable to the back of the Bridge Pod. Connect the Bridge Pod to Input 1 
on the front panel of the PowerLab (Figure 7). Connect the Stimulating Electrodes to the output on 
the front panel of the PowerLab. Follow the color scheme in Figure 7. Note that newer PowerLab 
Systems do not rely on the Bridge Pod.  
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Figure 7. Equipment Setup for PowerLab 26T 
 
3. Securely mount the Force Transducer and Manipulator/Micropositioner on the Ring Stand. 
4. Turn on the PowerLab. 
Calibrating the Force Transducer 
Raw output from the Force Transducer is in millivolts (mV). It needs to be calibrated to give the more 
meaningful units of Newtons (N). The Force Transducer also has some residual offset voltage that needs 
to be corrected for. 
 
1. Launch LabChart and open the settings file “Frog Muscle Settings” from the Experiments tab in the 
Welcome Center. It will be located in the folder for this experiment. ****BE SURE TO LOAD 2 
WINDOWS, ONE FOR EACH LIMB**** 
2. Select Bridge Pod from the Channel 1 Channel Function pop-up menu. Leave the Force Transducer 
undisturbed. Observe the signal (Figure 9) in the dialog. Zero this signal by turning the knob on the 
front of the Bridge Pod. Close the Bridge Pod pop-up menu.  
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Figure 9. Bridge Pod Dialog 
 
3. Start recording. Record for five seconds, and then hang a known weight (between 5–50 grams, 
provided by your instructor) from the Force Transducer. Record for a further five seconds, and Stop.   
4. Click-and-drag to select all the data. Select Units Conversion from the Channel 1 Channel Function 
pop-up menu (Figure 10).   
 
Figure 10. Units Conversion Dialog 
 
5. Select a small area when no weight was added, and click the arrow next to “Point 1.” 
6. Select a small area when the weight was added, and click the arrow next to “Point 2.” 
7. Enter the desired unit value in Newtons for each weight. Use the equation below: 
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Exercise 1a: Twitch Recruitment 
In this exercise, you will determine the effect of stimulus amplitude (strength) on contractile force- the 
force-intensity relationship.  
 
8. LabChart should be open. If not, open the settings file “Frog Muscle Settings.”  
9. Make sure the muscle is moist and is in contact with the electrodes. 
10. Zero the Bridge Pod. Use the same procedure as before. You do not need to calibrate the data. 
Note: For this exercise, you will be running a macro to apply a series of increasing stimuli. A macro is a 
recorded set of commands and operations that can be executed with a single command. 
11. Go to the Macro menu and select Recruitment to start the macro. Alternatively, you can press F2. 
LabChart will start recording, increase the stimulus on its own, and stop recording. (Do not click Start 
before playing the macro.)  
12. When the macro is finished, select “Save As” and save your data file to the desktop, but do not close 
the file. 
13. Scroll through your data and Autoscale, if necessary. Start at the end of the data and move toward 
the beginning. Determine the minimum voltage required to elicit the maximum contraction; this is the 
maximum excitation voltage.  
14. Multiply this voltage by 1.5. This new value is the supramaximal stimulus voltage. The supramaximal 
stimulus voltage will be used in each of the following exercises. 
15. Wait at least 30 seconds before moving on to the next exercise. Keep the muscle moist with saline 
solution. 
Exercise 2: Optimizing Muscle Length 
In this exercise, you will ensure that muscle length is optimal for force production.    
 
1. Make sure the muscle is moist and the electrodes are still positioned correctly. 
 
2. Zero the Bridge Pod as before. You do not need to calibrate the data.  
 
3. Note the position of the Manipulator/Micropositioner using the ruler.  
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4. Click on the data at the end of the last data block, and go to the Commands menu and select Add 
comment. Type “exercise 2” and click Add.  
 
5. Go to the Setup menu and select Stimulator Panel. In the Pulse Height text box, enter the value 
(in volts) for the supramaximal stimulus voltage calculated in Exercise 1. Do not adjust any other 
settings.  
6. Select Start to initiate a single twitch and Stop to end the recording 
7. Measure the force amplitude with the cursor  
8. Lengthen the muscle by 1mm using the micromanipulator and repeat steps 6 & 7.  
9. The optimal length has been reached once the force amplitude is unaltered for two successive twitch 
forces.  
Exercise 1b: Twitch Recruitment 
In this exercise, you will determine the effect of stimulus amplitude (strength) on contractile force at 
optimal length- the force-intensity relationship.  
 
16. LabChart should be open. If not, open the settings file “Frog Muscle Settings.”  
17. Make sure the muscle is moist and is in contact with the electrodes. 
18. Zero the Bridge Pod. Use the same procedure as before. You do not need to calibrate the data. 
Note: For this exercise, you will be running a macro to apply a series of increasing stimuli. A macro is a 
recorded set of commands and operations that can be executed with a single command. 
19. Go to the Macro menu and select Recruitment to start the macro. Alternatively, you can press F2. 
LabChart will start recording, increase the stimulus on its own, and stop recording. (Do not click Start 
before playing the macro.)  
20. When the macro is finished, select “Save As” and save your data file to the desktop, but do not close 
the file. 
21. Scroll through your data and Autoscale, if necessary. Start at the end of the data and move toward 
the beginning. Determine the minimum voltage required to elicit the maximum contraction; this is the 
maximum excitation voltage.  
22. If the maximal voltage is different than what was found in Exercise 1a, then multiply this voltage by 
1.5 and use it throughout the remaining following exercises. 
Exercise 3: Muscle Tetanus 
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In this exercise, you will examine the impact of stimulus frequency on muscle force production- the force-
frequency relationship.  
  
1. Make sure the muscle is moist and the electrodes are still positioned correctly. 
 
2. Zero the Bridge Pod as before, but do not calibrate the data.  
3. Click on the data at the end of the last data block, and go to the Commands menu and select Add 
comment. Type “exercise 2” and click Add.  
Note: For this exercise, you will be running a different macro to set up the Stimulator and record the 
data. Do not click Start before playing the macro. 
4. Go to the Macro menu and select Tetanus to start the macro. Alternatively, you can press F5. 
LabChart will start recording and will prompt you with messages. 
5. Follow the on-screen instructions. The PowerLab will stimulate the muscle for one second with 
repetitive pulses at intervals of 400 ms, 200 ms, 100 ms, 50 ms, and then 20 ms. Each recording will 
appear in a separate block. 
6. When the macro has finished, add a comment to each block of data with the stimulus interval as 
indicated above. Click on the data at the beginning of a data block, and go to the Commands menu 
and select Add comment. Type the stimulus interval and select the comment to be inserted at the 
selection. 
7. Save your data. Do not close the file. 
8. Wait at least 30 seconds before moving on to the next exercise. Make sure you keep the muscle 
moist with saline solution.    
Exercise 4: Muscle Fatigue 
In this exercise, you will examine muscle fatigue, evoked by prolonged tetanic stimulation of the muscle 
at 50 Hz for 30 seconds.  
 
1. Make sure the muscle is moist and the electrodes are still positioned correctly. 
 
2. Zero the Bridge Pod as before, but do not calibrate the data.  
3. Click on the data at the end of the last data block, and go to the Commands menu and select Add 
comment. Type “exercise 3” and click Add.  
Note: For this exercise, you will be running a final macro to stimulate the muscle repetitively. Do not 
click Start before playing the macro. 
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4. Go to the Macro menu and select Fatigue to start the macro. Alternatively, you can press F6. 
LabChart will start recording and will prompt you with messages. 
5. Follow the on-screen instructions. The PowerLab will stimulate the muscle with a stimulus interval of 
20 ms for 30 seconds. The recording duration of the macro is 45 seconds.  
6. Save your data and close the file. Complete exercises 1-4 with the contralateral limb using 
the second window you opened. If the same settings file/window is used, LabChart will 
begin the recruitment macro at the last stimulus intensity used- tetanus- which is not 
appropriate for a twitch.  
 
Copyright © 2010 ADInstruments Pty Ltd. All rights reserved. 
 
PowerLab® and LabChart® are registered trademarks of ADInstruments Pty Ltd. The names of specific 
recording units, such as PowerLab 8/30, are trademarks of ADInstruments Pty Ltd. Chart and Scope 
(application programs) are trademarks of ADInstruments Pty Ltd. 
 
www.ADInstruments. 
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Appendix D: -SMA Staining Protocol   
Materials 
24-well culture plates (Cat#: 3738, Corning Incorporated) 
PBS 
0.1% Saponin (Cat#: 47036, Sigma-Aldrich) 
2% Bovine Serum Albumin (Cat# B6917, Sigma Aldrich) 
Monoclonal Anti-Alpha Smooth Muscle Actin, Cy3 Conjugate (Cat#: C6198, Sigma-Aldrich) 
Slides 
Coverslips 
Parafilm 
Aluminum foil 
 
Staining 
1. Using forceps, remove muscle from PBS (stored in microcentrifuge tube at 4°C) and place in a 
single well of a 24-well culture plate. 
2. Prepare antibody solution containing 1:200 1A4 clone (alpha-smooth muscle actin, Cy3 
conjugate) in 0.1% saponin (reconstituted in PBS), 2% BSA (reconstituted in PBS) in PBS, 
using 0.3mL of solution per muscle. 
3. Incubate muscle in antibody solution for 3 nights (72 hours) at 4°C). (Note: Critical step—3 
nights crucial for bright staining) by gently pipetting solution over muscle.) 
4. Wash in 0.1% saponin in PBS 3x for 20 minutes at room temperature. Cover plate with foil 
during each wash. 
5. Wash in plain PBS for 30 minutes. Cover with foil during each wash. 
6. Place 1-2 drops of 50/50 PBS and Glycerol onto slide. 
7. Remove muscle from well using forceps and place on a slide. 
8. Add 1-2 drops of 50/50 PBS and Glycerol to the top of the muscle and place cover slips over 
the 
muscle. 
9. Paint edges of coverslip with clear nail polish to create a seal and prevent tissue desiccation. 
10. Store slides at 4°C wrapped in foil or an opaque container between imaging. 
 
Imaging 
11. Image using a standard fluorescent microscope. (Cy3 excitation: 550 nm, emission: 570 nm) 
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Appendix E: Gracilis Image Acquisition and Quantification  
 
1.0 PURPOSE 
This protocol serves as a reference checklist to analyze and quantify the 
paraformaldehyde fixed and fluorescent antibody stained alpha-smooth muscle actin of 
mice gracilis muscle under a wide field fluorescence microscope by 1) photographing 
three regions of collateral (stem, midzone, and reentry) and 2) analyzing their respective 
diameters using ImageJ’s straight line tool.  
2.0 Equipment 
• Fluorescent stained gracilis muscle slide 
• Computer 
• Fluorescence Microscope 
• ImageJ 
3.0 Methods 
3.1 Gracilis Image Acquisition 
 Obtain stained muscle slide from 
ISA. 
 Place under fluorescent 
microscope. 
 Focus slide through microscope 
 Open computer application. 
 Find profunda end of muscle. 
 Take a picture, rename, and save. 
 Move microscope field right 
allowing for image overlap on the left 
side. 
 Take a picture, rename, and save. 
 Repeat above 2 steps until you 
have reached the far-sided saphenous. 
 Lay stomach down (dorsal) 
3.2 Analysis of Gracilis Images 
 Open ImageJ 
 Open scale micrometer 
 Select straight-line tool 
• Draw a line across 
several graduations 
• Measure line (length) 
accordingly (in pixels) 
 Select Analyze 
• Set scale 
• Enter length (pixels) 
• Enter known length 
number  
• Enter units (microns) 
 Use straight-line tool 
(ctrl+m) to measure 3 
regions shown in Figure 1: 
• Collateral stem 
• Collateral midzone  
• Collateral reentery 
 
Figure 1: Three regions of gracilis that are to be analyzed: stem, midzone, and reentry.  
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Appendix F: Data Pad Lab Chart Reader Protocol for Data Acquisition 
 
Lab Chart Reader: Data Acquisition Data Pad Protocol 
I. Force-Intensity and Force-Frequency 
1. Remove “M” marker from chart view. 
2. In Data Pad toolbar, select Data Pad View  
3. Set up needed columns according to Figure 1 
a.  Click on the heading of Column A  
i. Click Comments on left 
ii. Click Full Comment Text on right 
iii. Under Calculation Source: select Stimulus Marker from drop-down menu 
b. Click on the heading of Column B  
i. Click Selection & Active Point on left 
ii. Click Time on right 
c. Click on heading of Column C 
i. Click Selection & Active Point on left 
ii. Click Value on right 
iii. Under Calculation Source: select Force from drop-down menu 
d. Click on heading of Column C and D 
i. Click Statistics on left 
ii. Click Maximum Value on right 
iii. Under Calculation Source: select Force from drop-down menu 
e. To find the difference in Force Production 
i. Change Data Pad to Cell edit mode in the top left corner of window signified 
by red circle in Figure 1 
ii. Click on the first cell in Column E (cell E1) 
iii. Type “=D1-C1”  
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Figure 1: Relevant Data for Force-Intensity Analysis 
 
4. Return to Chart View Window 
a. Select all data from Exercise 1B as shown in Figure 2 
**Note: Be sure to select all data  from 0.0s in 0.25mV to 1.0ms in 50Hz 
 
 
Figure 2: Selection of Exercise 1B in Chart View 
 
5. To populate Data Pad  
a. Select Multiple Add to Data Pad in Data Pad toolbar 
i. In Select field input “1.0” s” 
ii. For Step Through select Current Selection 
iii. Click Add button. 
6. Data values can then be copied and pasted into Excel 
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Figure 3: Example Data Pad Output for Force-Intensity and -Frequency 
 
II. Fatigue 
1. Place “M” marker at 0.00s in Fatigue window 
2. Click anywhere on fatigue curve to set sample parameters  
3. In Data Pad toolbar, select Data Pad View  
4. Set up needed columns according to Figure 4 
a. Click on Column G heading 
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i. Click Selection & Active Point on left 
ii. Click Time on Time on right 
b. Column H to J 
i. Click Statistics on left 
ii. Click the relevant measurement for each column on the right 
iii. Under Calculation Source: select Force from drop-down menu 
 
 
Figure 4: Relevant Data Needed for Fatigue Analysis 
 
5. Select Multiple Add to Data Pad in Data Pad toolbar 
a. In Select field input “1.0” s” 
b. For Step Through select Block containing selection 
c. Click Add button. 
6. Inactivate all other headings. 
a. Click on column heading. 
b. Select “Off”. 
7. Data values can then be copied and pasted into Excel 
**Note: use “Max Force Value” at 0.00s as 100% value when calculating percentages 
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Figure 5: Example Data Pad Output for Fatigue 
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Appendix G: Relevant Statistical Analysis for Force-Intensity Production Improvements 
General Linear Model: Force versus Interval, Group  
 
Method 
 
Factor coding (-1, 0, +1) 
 
 
Factor Information 
 
Factor  Type  Levels Values 
Interval Fixed   18 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, 2.25, 2.50, 2.75, 
             3.00, 3.25, 3.50, 3.75, 4.00, 4.25, 4.50 
Group   Fixed    4 Cells, Collagen, Control, Pocket 
 
 
Analysis of Variance 
 
Source       DF  Adj SS  Adj MS F-Value P-Value 
 Interval     17  29.323  1.7249   5.96  0.000 
 Group       3  33.471 11.1571  38.58  0.000 
 Interval*Group  51  1.979  0.0388   0.13  1.000 
Error       432 124.937  0.2892 
Total       503 203.116 
 
 
Model Summary 
 
    S  R-sq R-sq(adj) R-sq(pred) 
0.537779 38.49%   28.38%   12.66% 
 
Fisher Pairwise Comparisons: Response = Force, Term = Interval  
 
Grouping Information Using Fisher LSD Method and 95% Confidence 
 
Interval  N   Mean   Grouping 
4.50   28 1.07992 A 
4.25   28 1.05335 A 
3.75   28 1.04894 A B 
4.00   28 1.04599 A B 
3.50   28 1.02427 A B 
3.25   28 1.00178 A B 
3.00   28 0.97665 A B 
2.75   28 0.93990 A B C 
2.50   28 0.91738 A B C 
2.25   28 0.86465 A B C  
2.00   28 0.82123 A B C D 
1.75   28 0.81362 A B C D 
1.50   28 0.78538 A B C D 
1.25   28 0.73183   B C D 
1.00   28 0.64969    C D 
0.75   28 0.53074      D E 
0.50   28 0.28455       E F 
0.25   28 0.06904         F 
 
Means that do not share a letter are significantly different. 
* NOTE * Cannot draw the interval plot for the Fisher procedure. Interval plots for 
     comparisons are illegible with more than 45 intervals. 
